Trial Profile
Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose-escalation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Nemorubicin (Primary) ; Cisplatin
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nerviano Medical Sciences
- 14 Oct 2021 Status changed from recruiting to completed.
- 21 Jul 2012 Planned number of patients changed from 120 to 125 as reported in the European Clinical Trials Database record.
- 21 Jul 2012 Planned end date changed from 28 Mar 2009 to 28 Mar 2008 as reported in the European Clinical Trials Database record.